Stryker stock slips as 2026 outlook cut weighs on investors

Stryker lowered its 2026 outlook after third-quarter performance fell short of management expectations, according to the company release published by GlobeNewswire on October 29. Stryker stock traded at 285.15 euros on Lang & Schwarz at 17:07 CET on Wednesday, November 11, 2026, 1.66 percent below the Xetra close of Tuesday, November 10; the quote was also 1.18 percent below the 288.55 euros recorded in the latest relevant report at 15:01 CET the same day.

Third-Quarter Growth Was Uneven

For the quarter ended September 30, reported sales rose 7.7 percent to 6.52 billion US dollars, with organic sales growth at the same rate. MedSurg and Neurotechnology revenue increased 9.2 percent, while Orthopaedics revenue advanced 5.7 percent.

Reported net earnings fell 12.3 percent to 753 million US dollars, and diluted earnings per share declined 11.7 percent to 1.96 US dollars. A 293 million US dollar goodwill impairment was included in the reported result. Adjusted earnings per share rose 10.3 percent to 3.52 US dollars, while adjusted operating margin improved 60 basis points to 26.2 percent.

Lower Targets Shift Investor Focus

Stryker now expects 2026 organic sales growth of 6.5 percent to 7.0 percent, down from 8.3 percent to 9.3 percent previously. Adjusted earnings per diluted share are expected at 14.80 US dollars to 14.90 US dollars, compared with the former range of 14.95 US dollars to 15.10 US dollars.

Chief Executive Kevin Lobo said the quarter delivered good overall performance but fell short of expectations. Management still expects a solid fourth quarter and momentum heading into 2027. The revised targets increase the importance of procedure volumes, Orthopaedics execution and the preservation of margin gains.

What Comes Next For Investors

The company also repurchased 1.0 billion US dollars of common stock in the third quarter, while its board approved a 3.0 billion US dollar increase to the existing repurchase authorization in October. Capital allocation offers support, but it does not remove the operational test created by slower near-term growth.

Broader market direction remains relevant for medical-technology shares; investors can follow the S&P 500 market environment.

More news and analyses are available on the Stryker stock topic page.